Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial

Boris Jülg; Victoria E. Walker-Sperling; Kshitij Wagh; Malika Aïd; Kathryn E. Stephenson; Rebecca Zash; Jinyan Liu; Joseph P. Nkolola; Amelia Hoyt; Mike Castro; Leonid Serebryannyy; Katherine E. Yanosick; Tessa Speidel; Erica N. Borducchi; Tetyana Murzda; Lori F. Maxfield; Roberto C. Arduino; Adrian B. McDermott; Lúcio Gama; Elena E. Giorgi; Richard A. Koup; Michael S. Seaman; Charlotte-Paige Rolle; Edwin DeJesus; Wenjun Li; Bette Korber; Dan H. Barouch

doi:10.1038/s41591-024-03247-5

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Human immunodeficiency virus type 1 (HIV-1)-specific broadly neutralizing monoclonal antibodies (bNAbs) have to date shown transient viral suppression when administered as monotherapy or as a cocktail of two antibodies

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Jülg et al. (2024) studied this question.

synapsesocial.com/papers/68e58a69b6db6435875269ed https://doi.org/10.1038/s41591-024-03247-5

View Full Paper

Ask AI

Bookmark

Share

Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial

Ask about this paper

Abstract

Discussion

Cite This Study

Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading